oncolytic virus

Phase 1Biologic

TThe First Affiliated Hospital of Bengbu Medical University

oncolytic virus is one of 111 biologic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

GlioblastomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

LymphomaPhase 1

Active, not recruiting

GlioblastomaPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncaspar

SServier

Preclinical

15 2

Tafasitamab

Incyte

Preclinical

7 3

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 4

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

PEG-Intron

Merck & Co.

Preclinical

1 7

oncolytic virus

TThe First Affiliated Hospital of Bengbu Medical University

Phase 1

1 8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

2 10

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Glioblastoma

NCT07145047

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors5 trials

A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors

Unknown status·TThe First Affiliated Hospital of Bengbu Medical University·Phase 1·NCT05205408·7 enrolled

A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors

Unknown status·WWuxi People's Hospital·Phase 1·NCT05136937·18 enrolled

Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

Recruiting·—·Phase 1·NCT06346041·19 enrolled

Show 2 more trials

A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors

Unknown status·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1·NCT05228119·50 enrolled

Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors

Unknown status·NNorth China Petroleum Bureau General Hospital·Phase 1·NCT04787003·50 enrolled

Glioblastoma1 trial

Clinical Study of Oncolytic Virus in Glioblastoma

Recruiting·MMianyang Central Hospital·Phase 1/2·NCT07145047·20 enrolled

Lymphoma1 trial

Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma

Unknown status·TThe First Affiliated Hospital of Bengbu Medical University·Phase 1·NCT05387226·6 enrolled

Small Cell Lung Cancer1 trial

A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer

Unknown status·TThe First Affiliated Hospital of Bengbu Medical University·Phase 1·NCT05205421·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for oncolytic virus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — oncolytic virus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for oncolytic virus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Bengbu Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe First Affiliated Hospital of Bengbu Medical University

oncolytic virus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Patients With Advanced Solid Tumors5 trials

Glioblastoma1 trial

Lymphoma1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News